Form 8K Coherus BioSciences Inc For: 17 August
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Coherus BioSciences Inc (CHRS)
The Coherus BioSciences share price today is 1.370, view NASDAQ CHRS stock exchange data. Track the latest Coherus BioSciences share price with real-time updates on CHRS stock performance including market cap, day range, 52-week range and dividend yield. Access CHRS charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.310
1.410
52 wk Range
1.090
2.616
CHRS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.3101.410
52 wk Range
1.0902.616
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CHRS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
7.750
Upside
+465.69%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Form 8K Coherus BioSciences Inc For: 15 June- Investing.com
- Form 8K Coherus BioSciences Inc For: 17 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.750
(+465.69% Upside)
Coherus BioSciences Inc SWOT Analysis
Oncology Pivot | Coherus BioSciences transitions from biosimilars to immuno-oncology, facing challenges and opportunities in its strategic transformation |
Casdozo's Promise | Explore the potential of casdozo, Coherus's anti-IL-27 antibody, showing encouraging results in liver cancer treatment and driving pipeline advancement |
Financial Tightrope | Delve into Coherus's complex financial landscape, balancing debt obligations and cash burn against the need to fund ongoing research and development |
Market Dynamics | Analysts set price targets ranging from $1.50 to $7.00, reflecting varied perspectives on Coherus's ability to navigate competitive pressures and pipeline potential |
Coherus BioSciences Inc Earnings Call Summary for Q2/2026
- Coherus posted Q2 2026 adjusted EPS of -$0.19, beating consensus of -$0.26, though revenue of $14.31M missed estimates by $100K; shares fell 4.14% after-hours.
- LOQTORZI net sales rose 15% quarter-over-quarter to $13.6M; company maintained full-year revenue guidance of $57M-$62M and operating expense outlook of $170M-$175M.
- Operating expenses declined sharply with R&D down 18.6% to $21.4M and SG&A down 19.2% to $21M year-over-year, marking sixth consecutive quarter of SG&A reductions.
- Cash position fell to $105.3M from $167M prior quarter, primarily due to $39M in UDENYCA divestiture transition obligations expected to ease by year-end.
- Management expects clinical data updates in Q4 2026, including mature tagmokitug head/neck data in October and initial HCC program results; Phase III planning for casdozokitug.
Last Updated: 06-08-2026, 03:32 am
Read Full TranscriptEarnings
Latest Release
05-08-2026
EPS / Forecast
-0.19 / -0.26
Revenue / Forecast
14.31M / 14.41M
Compare CHRS to Peers and Sector
Metrics to compare | CHRS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCHRSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −5.1x | −0.4x | |
PEG Ratio | 0.01 | 0.03 | 0.00 | |
Price/Book | 3.4x | 3.2x | 2.6x | |
Price / LTM Sales | 4.1x | 2.2x | 3.1x | |
Upside (Analyst Target) | - | 85.5% | 49.3% | |
Fair Value Upside | Unlock | −5.9% | 6.7% | Unlock |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Coherus BioSciences (CHRS) Share Price Today?
The Coherus BioSciences share price today is 1.370.
What is the current Coherus BioSciences (CHRS) share price and day range?
As of 25-08-2026, the Coherus BioSciences share price is 1.370, with a previous close of 1.360. The share price has ranged from 1.310 to 1.410 today, while the 52-week range spans from 1.090 to 2.616.
What Is the Coherus BioSciences Market Cap?
As of today, Coherus BioSciences market cap is 208.580M.
What Is the Coherus BioSciences (CHRS) Share Price Target?
The average 12-month share price target for Coherus BioSciences is 7.750, with a high estimate of 10 and a low estimate of 4. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +465.69% Upside potential.
What Is Coherus BioSciences's Earnings Per Share (TTM)?
The Coherus BioSciences EPS (TTM) is -1.221.
When Is the Next Coherus BioSciences Earnings Date?
Coherus BioSciences will release its next earnings report on 09-11-2026.
From a Technical Analysis Perspective, Is CHRS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Coherus BioSciences Trade On?
Coherus BioSciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Coherus BioSciences?
The stock symbol for Coherus BioSciences is "CHRS."
How Many Times Has Coherus BioSciences Stock Split?
Coherus BioSciences has split 0 times.
How Many Employees Does Coherus BioSciences Have?
Coherus BioSciences has 144 employees.
What Is the CHRS Premarket Price?
CHRS's last pre-market stock price is 1.379. The pre-market share volume is 40.000, and the stock has changed by 0.019, or 1.400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.